Effect of Dexamethasone on Labour Induction in Term Pregnancies
Cairo University
150 participants
May 1, 2025
INTERVENTIONAL
Conditions
Summary
The aim of the study is to assess the effect of dexamethasone on labour induction in term pregnancies. Primary outcome: The interval between initiation of induction and beginning of the active phase of labour. Secondary outcomes: * Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation). * Duration of second stage of labour * Mode of delivery. * Fetal outcome. Group A: Will receive one dose of IM dexamethasone sodium phosphate 8 mg (2 mL). Group B: Will receive vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h. Group C: Will receive one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.
Eligibility
Inclusion Criteria6
- Age > 18 years.
- Nulliparous.
- Vertex presentation.
- Singleton pregnancy.
- Gestational age ≥ 39 weeks according to a reliable date for the last menstrual period or a first-trimester ultrasound evaluation.
- No contraindication for vaginal delivery.
Exclusion Criteria5
- Indication for cesarean section e. g. Placenta previa, intrauterine growth retardation, non-vertex presentation and previous cesarean section.
- Maternal medical disorders as diabetes mellitus and severe pre-eclampsia.
- Preterm labour and preterm rupture of membranes.
- Gestational age <39 weeks of gestation.
- Fetal macrosomia > 4kg (estimated by u/s).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
one dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction
vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.
one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07109258